Galera Adopts Limited Duration Stockholder Rights Agreement
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq:GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests.
Related news for (GRTX)
- Galera Therapeutics completes acquisition of Nova Pharmaceuticals
- Galera Announces Board Approval of Complete Liquidation and Dissolution
- Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
- Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates